Recombinant Human Plasminogen Activator Inhibitor 2 (SERPINB2) Protein (His)

Name: Recombinant Human Plasminogen Activator Inhibitor 2 (SERPINB2) Protein (His)
Brand: Beta LifeScience
SKU: BLC-02811P
Price: 349.0 USD
Availability: InStock

Greater than 85% as determined by SDS-PAGE.

Collections: Other recombinant proteins, Recombinant proteins, Recombinant proteins fall special offers - full-length proteins, Recombinant proteins holiday sale

Price Save $883

Size

100ug

Submit an inquiry or email sales for a custom bulk quote. Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Plasminogen Activator Inhibitor 2 (SERPINB2) Protein (His) is produced by our Mammalian cell expression system. This is a full length protein.
Purity	Greater than 85% as determined by SDS-PAGE.
Uniprotkb	P05120
Target Symbol	SERPINB2
Synonyms	HsT1201; Monocyte Arg serpin ; Monocyte Arg-serpin; Monocyte Arginine-serpin; Monocyte-derived plasminogen activator inhibitor; PAI; PAI-2; PAI2 ; PAI2_HUMAN; Placental plasminogen activator inhibitor; PLANH2 ; Plasminogen activator inhibitor 2; plasminogen activator inhibitor; type 2; plasminogen activator inhibitor; type II (arginine-serpin); serine (or cysteine) proteinase inhibitor; clade B (ovalbumin); member 2; Serpin B2; serpin peptidase inhibitor; clade B (ovalbumin); member 2; Serpinb2; Urokinase inhibitor
Species	Homo sapiens (Human)
Expression System	Mammalian cell
Tag	N-10His
Target Protein Sequence	MEDLCVANTLFALNLFKHLAKASPTQNLFLSPWSISSTMAMVYMGSRGSTEDQMAKVLQFNEVGANAVTPMTPENFTSCGFMQQIQKGSYPDAILQAQAADKIHSSFRSLSSAINASTGNYLLESVNKLFGEKSASFREEYIRLCQKYYSSEPQAVDFLECAEEARKKINSWVKTQTKGKIPNLLPEGSVDGDTRMVLVNAVYFKGKWKTPFEKKLNGLYPFRVNSAQRTPVQMMYLREKLNIGYIEDLKAQILELPYAGDVSMFLLLPDEIADVSTGLELLESEITYDKLNKWTSKDKMAEDEVEVYIPQFKLEEHYELRSILRSMGMEDAFNKGRANFSGMSERNDLFLSEVFHQAMVDVNEEGTEAAAGTGGVMTGRTGHGGPQFVADHPFLFLIMHKITNCILFFGRFSSP
Expression Range	1-415aa
Protein Length	Full Length
Mol. Weight	50.1 kDa
Research Area	Cell Biology
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Inhibits urokinase-type plasminogen activator. The monocyte derived PAI-2 is distinct from the endothelial cell-derived PAI-1.
Subcellular Location	Cytoplasm. Secreted, extracellular space.
Protein Families	Serpin family, Ov-serpin subfamily
Database References	HGNC: 8584 OMIM: 173390 KEGG: hsa:5055 STRING: 9606.ENSP00000299502 UniGene: Hs.594481

Gene Functions References

miR-15a was identified as a downregulated miRNA in CCFs. Moreover, PAI-2 was identified as a novel target gene of miR-15a. PMID: 29347950
Single nucleotide polymorphisms in ICAM1 (rs1799969) and SERPINB2 (rs6103) genes were found to be protective against thalidomide-induced peripheral neuropathy (TiPN). In children with inflammatory bowel disease, TiPN is common but mild and generally reversible. Cumulative dose seems to be the most relevant risk factor, whereas polymorphisms in genes involved in neuronal inflammation may be protective. PMID: 28817461
serpinB2 bound to and stabilized p21 to mediate senescence in a proteasome-independent manner, indicating that serpinB2 has a direct role in senescence. Thus, this study reveals a unique mechanism by which serpinB2 maintains senescence through stabilization of p21 protein levels. PMID: 28794016
findings demonstrate the prospective role of SerpinB2 as a novel biomarker for acquired gefitinib resistance and a potential target for non-small cell lung cancer treatment. PMID: 27558531
SerpinB2 promotes miR-200c/141 cluster overexpression-induced breast cancer cell metastasis PMID: 28427146
PAI-2 likely plays a key role in cardiovascular disease through multiple pathophysiologic processes including racial dependency, platelet clot initiation and propagation, oxidative stress, inflammation effects on HDL metabolism and coagulation PMID: 27174532
This study is the first to associate enhancer RNAs with SERPINB2 and is the first demonstration of acquisition of NELF binding by enhancer RNAs on chromatin. PMID: 28578223
This study establishes a novel role for SerpinB2 in the stromal compartment in pancreatic ductal adenocarcinoma invasion through regulation of stromal remodelling PMID: 28346421
The variant of PAI-2 gene was associated with coronary artery disease and recurrent coronary event risk in Chinese Han population, in Xinjiang. PMID: 26573152
SerpinB2 plays an important role in proteostas PMID: 26083412
Polymorphisms in this fibrinolytic system gene are associated with recurrent spontaneous abortion in Sinhalese women, probably through impaired implantation. PMID: 25444509
PAI-2 was up-regulated in tensioned keloid fibroblasts and normal fibroblasts, but more so in keloid cells. Knockdown of PAI2 reduced cell proliferation in fibroblasts under tension. PMID: 25046655
Soluble guanylate cyclase activators might alleviate or reverse vascular remodeling in pulmonary hypertension through the up-regulation of PAI-2. PMID: 25704756
We found no association between allele frequency and risk of multiples sclerosis for any single nucleotide polymorphism investigated for serpinb2 PMID: 23897640
A role for SERPINB2 in patients with head and neck squamous cell carcinoma. PMID: 23661500
Plasminogen activator inhibitor-2 polymorphism associates with recurrent coronary event risk in patients with high HDL and C-reactive protein levels. PMID: 23874812
PSMB1 is part of the transcriptional machinery required for gastrin stimulated expression of PAI-2 and Reg1. PMID: 23544109
SerpinB2 can be induced by lentiviral infection in vivo. PMID: 23460840
Low expression of PAI-2 serves as a novel marker of portal vein tumor embolism and poor prognosis for hepatocellular cancer. PMID: 23188538
Increased expression of SerpinB2 by an inflammatory stimulus is sufficient to generate structures that resemble secretory vesicles. PMID: 23474086
PAI-2 expression may be negatively associated with the invasive potential of hepatocellular carcinoma (HCC). PMID: 23527801
a model for the transcriptional control of the human PAI-2 gene PMID: 22334683
Data suggests that PAI-2, in endothelial cells induced with inflammatory stimuli, can inhibit proteasome and thus tilt the balance favoring proapoptotic signaling. PMID: 21976669
High PAI-2 expression is associated with poor treatment response in colorectal carcinoma. PMID: 21744990
Plasminogen activator inhibitor-2 (PAI-2) secreted from activated mast cells induces alpha-smooth muscle actin (alpha-SMA) expression in dermal fibroblasts PMID: 21477997
Our results suggest that P. intermedia may contribute to periodontal tissue destruction by upregulating tPA and PAI-2 expression in hPDL cells via multiple signaling pathways. PMID: 21314733
The decrease in plasma PAI-2 observed in preeclampsia does not precede the clinical onset of the disease. PMID: 20205627
Results describe periodontal treatment effects on gingival crevicular fluid (GCF) interleukin-6 (IL-6), tissue-type plasminogen activator (tPA), plasminogen activator inhibitor-2 (PAI-2), albumin levels in type 2 diabetic patients. PMID: 20845058
HPV-transformed CaSki cells express high levels of SerpinB2, with cellular distribution, glycosylation, secretion, cleavage, induction and urokinase binding similar to that for primary cells; SerpinB2 efficiently binds the proteasomal subunit member beta1 PMID: 20974129
PAI-2 has a role in promoting the differentiation of human epidermal keratinocytes. PMID: 20494554
It is feasible to detect fetal trisomy 18 non-invasively by maternal plasma SERPINB2 RNA-SNP analysis provided that sufficient quantities of plasma samples are used. PMID: 19650060
regulator of monocyte proliferation and differentiation PMID: 11929770
plasminogen activator inhibitor type 2: potential prognostic factor for endometrial carcinomas PMID: 11949838
Identification of plasminogen activator inhibitor-2 as a gastrin-regulated gene PMID: 12105855
post-transcriptional regulation of the PAI-2 gene is modulated by tristetrapolin PMID: 12578825
Data suggest that the CD-loop functions as a redox-sensitive switch that converts plasminogen activator inhibitor type 2 (PAI-2) between an active stable monomeric and a polymerogenic conformation. PMID: 12682008
These results indicate that PAI-2 may enhance Rb's tumor suppressor activity and suggest a potential therapeutic role for PAI-2 against HPV-transformed lesions. PMID: 12944478
evidence that a polymorphism of the PAI-2 gene is associated with an increased risk of myocardial infarction PMID: 14653443
PAI-2 has a role in scleroderma, as seen by its expression in fibroblasts PMID: 15500643
PAI-2 expression has a potent suppressive effect on human papillomavirus type 18 oncogene transcription mediated by Rb and LIP, a finding with potential implications for prognosis and treatment of human papillomavirus-transformed lesions. PMID: 15767426
PAI2 is present in normal conjunctiva. PMID: 15887231
investigated the unique mousetrap inhibition mechanism of serpins through saturation mutagenesis of the P8 residue for PAI-2 PMID: 16214170
the urokinase/PAI-2 complex is a new high affinity ligand for the endocytosis receptor low density lipoprotein receptor-related protein PMID: 16459332
SerpinB2 is a potentially important inducible host factor that significantly promotes HIV-1 replication PMID: 16923810
in patients with complex congenital malformations amniotic fluid levels of plasminogen activator inhibitor type 2(PAI2) PMID: 17141398
Data indicate that this family did not follow the Mendelian inheritance pattern; the Ser(413)/Ser genotype in 60% of the affected members might increase the risk for autoimmune syndromes such as anti-phospholipid syndrome or systemic lupus erythematosus. PMID: 17657675
PAI-2 is able to inhibit and clear urokinase plasminogen activator activity without initiating mitogenic signalling events through the very-low-density-lipoprotein receptor (VLDLr). PMID: 17696882
Type 2 diabetes in this study seems not to increase gingival crevicular fluid levels of the evaluated inflammatory mediators PAI2. PMID: 18472001
SerpinB2 is a cell survival factor that modulates Rb repression of proapoptotic signal transduction PMID: 18632617
PAI-2 can inhibit cell-bound tPA activity in vitro and thus prevent plasmin formation PMID: 18690354

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.